A 3 3 5 -A 7 6 6 was based on the average monthly salary in the UK. A conservative assumption was made about the increased risk of a productive day being lost -associated with level of patient satisfaction to their treatment -by calculating an approximate number of unscheduled hospitalisations that users of a new inhaler would experience in the previous 12 months relative to Spiriva® HandiHaler®. Patient satisfaction with their inhaler was based on inhaler features that relate to ease of use and ergonomics and compared Spiriva® HandiHaler® to an improved inhaler. Results: The frequency of unscheduled hospitalisations for the new inhaler and Spiriva® HandiHaler® users were calculated at 0.34 and 0.38, resulting in 68 and 76 productive days lost annually, respectively. The total annual societal cost per patient was € 9,851 with the new inhaler and € 10,891 with Spiriva® HandiHaler®. The new inhaler costs € 1,040 less per annum than Spiriva® Handihaler®. ConClusions: New inhalers with improved features have the potential to offer substantial societal cost savings in COPD compared with Spiriva® Handihaler®.
objeCtives: A real-life cost-effectiveness evaluation in 2008 showed that medication costs of budesonide/formoterol for maintenance and reliever therapy (MART) via dry powder inhaler (DPI) was significantly lower than medication costs associated with fixed-dose combination (FDC) of budesonide/formoterol in conventional way (FDC of ICS/LABA + additional reliever) and free adjustable combination (FAC) of budesonide and formoterol, with at least equal effectiveness. In 2014 the Dental and Pharmaceutical Benefits Agency (TLV) in Sweden assessed all inhaled corticosteroids (ICS), long-acting beta-2-agonists (LABA) and their FDCs where the outcomes suggested equal effectiveness across treatment strategies and a pricing corridor was implemented. The objective is to update the medication costs for a real-life costeffectiveness analysis of treating asthma in Swedish primary care and to evaluate the medication costs in Denmark. Methods: Medication costs from 2006 included all pharmaceuticals in the analysis which were inflated to 2015 price levels and then compared to today's actual prices of medications used in the FAC arm (Pulmicort® Turbuhaler® & Oxis® Turbuhaler®, plus terbutaline as needed), FDC arm (Bufomix® Easyhaler® plus terbutaline as needed) and the budesonide/formoterol MART arm (DuoResp® Spiromax®). The same analysis was conducted for both Sweden and Denmark. Results: The medication costs in the budesonide/formoterol MART arm is less costly when considering DuoResp® Spiromax®, SEK 3336.4 (SEK 4710.9) per patient and year compared to SEK 4163 (SEK 6157) in the FDC arm and SEK 7498.5 (SEK 5637.6) FAC arm. In Denmark the same trend is visible where the MART arm was DK 4183.5 (DK 4573) compared to DK 4579 (DK 5905.2) in the conventional FDC arm and 4510.4 (DK 4511.7) in the FAC arm. ConClusions: Compared to conventional treatment arm (FDC + reliever) and free adjustable combination (FAC) arm, DuoResp® Spiromax® with MART usage has the potential to be cost saving option with at least equivalent efficacy.
PRS41 coSt-eFFectiveneSS analySiS oF the Fixed coMBination indacateRol/ GlycoPyRRoniUM vS. tiotRoPiUM and SalMeteRol/ FlUticaSone in the ManaGeMent oF coPd in GReece
Geitona M 1 , Kousoulakou H 1 , Kalogeropoulou M 2 , Mitsiki E 2 , Panitti E 2 , Steiropoulos P 3 1 University of Peloponnese, Corinth, Greece, 2 Novartis Hellas, Metamorfosis, Greece, 3 Democritus University of Thrace, Alexandroupoli, Greece objeCtives: This study aimed at estimating the cost-effectiveness of the fixed-dose combination indacaterol/glycopyrronium 85/43μ g (IND/GLY) against tiotropium 18μ g (TIO) and salmeterol/ fluticasone 50/500μ g (SFC) in the management of patients with COPD in Greece. Methods: A microsimulation model was developed in MS Excel. Efficacy and utility data were obtained from the international literature (SHINE & ILLUMINATE studies) and mortality data from the WHO database. Distribution of patients by GOLD severity stage, maintenance costs and costs associated with severe/ non-severe exacerbations were taken from published Greek studies. Unit costs were taken from officially published sources (Price Bulletin, reimbursement list, DRGs). The study perspective was that of the Social Insurance Fund; costs and outcomes were discounted at 3.5%; outcomes are reported over time horizons of one, three, five and 10 years and over a lifetime. (r = 0.09 with Spearman and Pearson tests). ConClusions: There is a decrease in the COPD hospitalizations after the introduction of the new inhaled medicines and increase in their cost due to increase in the cost of services.
PRS37 dUal BRonchodilation With Qva149 in PatientS With SeveRe and veRy SeveRe coPd -aRe theRe incReMental BeneFitS FoR PoRtUGUeSe PatientS and FoR the PoRtUGUeSe nhS When coMPaRed With cURRent tReatMent oPtionS in PoRtUGal?
Carrasco J 1 , Viriato D 2 , Cardoso I 2 1 Novartis Farma Portugal, Porto Salvo, Portugal, Porto Salvo, Portugal objeCtives: Long-acting β 2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) have shown efficacy in preventing exacerbations in patients with COPD. Though these agents are effective in the treatment of COPD, deterioration in the patient health status can persist and therefore there is a need for improved treatment outcomes. In the SPARK trial, dual bronchodilation with QVA149 demonstrated advantages in reducing the risk of COPD exacerbations in severe and very severe patients when compared to single bronchodilation with tiotropium. The objective of the study was to stimate the clinical benefits and the budget impact associated with the use of indacaterol 110 μ g/glycopyrronium 50 μ g (QVA149) instead of tiotropium 18 μ , in severe and very severe COPD patients (GOLD C and D) in Portugal. Methods: A cost-consequence model was developed using the SPARK study data to derive treatment outcomes associated to the use of QVA149 instead of tiotropium. Primary outcomes of interest were COPD exacerbations and direct cost for the NHS. Treatment outcomes and costs were estimated for a 1 year. Local data was used to identify the target population, resource use and overall treatment costs. Results: It is estimated that there are 11,239 GOLD C and D patients treated with tiotropium. Assuming that 20.5% of COPD patients see their primary care doctor with complaints about symptoms and exacerbations 2,304 of those patients could be treated instead with QVA149. After 1 year of treatment with QVA 149 it is estimated that patients will experience 1,291 fewer exacerbations with a reduction of € 136,544 in the overall treatment costs compared to treatment with tiotropium. ConClusions: Symptom control in COPD is essential and evidence shows that dual bronchodilation with QVA149 brings benefits when compared to tiotropium. The use of QVA149 in symptomatic patients instead tiotropium may improve treatment outcomes and reduce overall costs for the Portuguese NHS.
PRS38 can Qva149 iMPRove ShoRt teRM oUtcoMeS in PatientS With coPd WithoUt incReaSinG the oveRall tReatMent coStS FoR the PoRtUGUeSe nhS? oPtiMizinG tReatMent oUtcoMeS With a ReSPonSiBle USe oF liMited ReSoURceS
Carrasco J 1 , Viriato D 2 , Cardoso I 2 1 Novartis Farma Portugal, Porto Salvo, Portugal, Porto Salvo, Portugal objeCtives: In the LANTERN study QVA149 significantly reduced the rate of moderate or severe exacerbations by 31% (p= 0.048) over Salmeterol/Fluticasone (SFC). The evidence suggests that the use of QVA149 can optimize treatment outcomes in patients with mild-to-severe COPD but at what cost to the Portuguese NHS?
The study objective was to quantify the potential clinical benefits and the budget impact associated with the use of QVA149 and SFC in the treatment of Portuguese patients with moderate-to-severe COPD with few or no exacerbations. Methods: A cost-consequence model was developed using the LANTERN study data to derive treatment outcomes for QVA149 and SFC. Primary outcomes of interest were COPD exacerbations (total, moderate and severe) and direct cost for the Portuguese NHS. Treatment outcomes and costs were estimated for 1 year time horizon. Local data was used to identify the target population, resource uses and overall treatment costs. Results: It is estimated that there are 73,739 GOLD B patients diagnosed and treated in Portugal and 34,778 of those patients are treated with SFC and could be eligible to receive treatment with QVA149. After one year of treatment with SFC it is estimated that these patients may experience 30,605 exacerbations (15,650 moderate/severe) with a total treatment cost of € 69,268,710. If treated with QVA149 it is estimated that these patients may experience 6,608 fewer exacerbations (4,869 fewer moderate/severe) with a total treatment cost saving of € 8,524,307 versus SFC treatment. ConClusions: The analysis suggest that once a day QVA149 can provide better treatment outcomes in patients with COPD with fewer treatment costs for the Portuguese NHS when compared with twice a day SFC in the treatment of moderate-to-severe COPD with few or no exacerbations.
PRS39 the Potential Societal coSt BeneFitS oF incReaSinG Patient SatiSFaction By USinG an inhaleR With iMPRoved FeatUReS coMPaRed to SPiRiva® handihaleR® FoR the ManaGeMent oF chRonic oBStRUctive PUlMonaRy diSeaSe (coPd) in the Uk
Nicolai JL 1 , Torvinen S 1 , Comberiati U 1 , Miles R 2 , Greaney MH 2 , Howard DJ 2 , Plich A 1 1 Teva Pharmaceuticals Europe B.V., Amsterdam, The Netherlands, 2 Adelphi Values Ltd, Bollington, UK objeCtives: Spiriva® Handihaler® (tiotropium) is available in a single capsule dry powder inhaler (DPI) for the treatment of COPD. As exacerbations and hospitalisations represent an important driver of the cost and morbidity of COPD, high priority should be given to interventions aimed at delaying the progression of disease, preventing exacerbations, and reducing the risk of comorbidities to alleviate the clinical and economic burden of disease. The potential societal cost benefits of improving treatment satisfaction, due to improved characteristics of an inhaler were investigated. Methods: The eligible adult patient population was based on confirmed COPD diagnoses in UK, with the proportion of patients receiving Spiriva® Handihaler® based on market research data. The annual number of work days lost due to COPD was based on data from the UK. The monetary value of a productive day
